WeVote
Log In

Bill

Bill

SF 4485

Psilocybin therapeutic use program establishment

2025-2026 Regular Session Introduced by Jim Abeler and 3 co-sponsors

Minnesota bill establishes regulated psilocybin-assisted therapy program for licensed medical providers treating qualifying conditions in supervised clinical settings.

Referred to Health and Human Services
#drugsandmedicine #healthandhealthdepartment
0
WeVote Research Nonpartisan
Bill Summary · SF 4485

Legislative bill overview

SF 4485 establishes a regulated therapeutic use program for psilocybin in Minnesota, creating a framework for administering psilocybin-assisted therapy under medical supervision. The bill would allow licensed practitioners to administer psilocybin to patients with qualifying conditions in controlled clinical settings.

Why is this important

Psilocybin research has shown promising results for treatment-resistant depression, PTSD, and end-of-life anxiety, yet federal Schedule I classification prevents most clinical use. This bill could provide Minnesota residents access to an emerging therapeutic option while generating data on safety and efficacy within a regulated system.

Potential points of contention

  • Federal-state conflict: Psilocybin remains a Schedule I controlled substance federally, creating legal tension between state authorization and federal law enforcement priorities
  • Practitioner licensing and training: Establishing standards for who can administer therapy, how they're trained, and what credentials are required remains undefined
  • Access and equity: Questions about insurance coverage, cost, and whether the program will be available to low-income patients or primarily accessible to wealthy individuals
  • Long-term safety data: While preliminary research is encouraging, long-term effects and potential adverse outcomes in broader populations remain under study

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.